Physician profile
Derrick L Butler
NPI 1366487225
$691,736.22
in general payments reported to CMS, 2019-2025
17 companies · $155K in 2025
The $155K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $21K · 2021: $31K · 2022: $160K · 2023: $116K · 2024: $88K · 2025: $155K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $265K · Travel and Lodging: $74K · Food and Beverage: $13K · Consulting Fee: $7,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $264,877.00 |
| Travel and Lodging | $74,169.62 |
| Food and Beverage | $12,646.36 |
| Consulting Fee | $7,405.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $441,553.97 | 2021-2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $177,694.14 | 2019-2025 | Biktarvy, Yeztugo |
| Janssen Products, Lp | $54,246.17 | 2019-2022 | |
| Viiv Healthcare Company | $16,109.59 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Theratechnologies INC. | $750.00 | 2021 | |
| Novo Nordisk INC | $245.86 | 2025 | Wegovy, Ozempic |
| Janssen Biotech, INC. | $227.12 | 2019-2022 | |
| Napo Pharmaceuticals INC | $210.83 | 2019-2024 | Mytesi |
| Abbvie INC. | $159.61 | 2024 | |
| Merck Sharp & Dohme LLC | $136.66 | 2019-2024 | Delstrigo, Pifeltro |
| Indivior INC. | $120.26 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $85.05 | 2022-2023 | Xarelto |
| Janssen Scientific Affairs, LLC | $80.52 | 2021-2023 | Symtuza |
| Emd Serono, INC. | $50.41 | 2024 | |
| Alkermes, INC. | $29.73 | 2024 | Vivitrol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $18.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.